Combined use of nonmyelosuppressive nitrosourea analogues with hydroxyurea in the induction of F-cell production in a human erythroleukemic cell line

Experimental Hematology

Volumn 31, Issue 7, 2003, Pages 592-600

  Iyamu, Efemwonkiekie W ^a   Adunyah, Samuel E ^d   Fasold, Hugo ^e   Horiuchi, Kazumi ^a   Baliga, Surendra ^f   Ohene Frempong, Kwaku ^a   Turner, Ernest A ^b   Asakura, Toshio ^a,c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MEHARRY MEDICAL COLLEGE   (United States)

^e GOETHE UNIVERSITY   (Germany)

^f UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [3 (2 CHLOROETHYL)UREIDO] 2 DEOXY DEXTRO GLUCOPYRANOSE; 2 [3 (2 METHYL 2 NITROSO)UREIDO] 2 DEOXY DEXTRO GLUCOPYRANOSE; BENZIDINE; HEMOGLOBIN F; HYDROXYUREA; NITROSO DERIVATIVE; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ARTICLE; BURST FORMING UNIT; CELL COUNT; CELL STRAIN K 562; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ERYTHROBLAST; ERYTHROID PRECURSOR CELL; ERYTHROLEUKEMIA; HEMOGLOBIN DETERMINATION; HEMOGLOBIN SYNTHESIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN INDUCTION; QUANTITATIVE ANALYSIS; SICKLE CELL ANEMIA;

EID: 0038722133     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(03)00105-X     Document Type: Article

References (42)

1. Steinberg M.H., Hebbel R.P. Clinical diversity of sickle cell anemia: genetic and cellular modulation of disease severity. Am J Hematol. 14:1986;405-416.
2. Powars D., Chan P., Schreoder W.A. The variable expression of sickle cell disease is genetically determined. Semin Hematol. 27:1990;360-376.
3. Schechter A.N., Noguchi C.T., Rodgers G.P. Sickle cell disease. Stamatoyannaopoulos G., Nienhuis A.W., Leder P., Majerus P.W. Molecular Basis of Blood Diseases. 1987;187 Saunders, Philadelphia.
4. Noguchi C.T., Schechter A.N. The intracellular polymerization of sickle hemoglobin and its relevance to sickle cell disease. Blood. 58:1981;1057-1068.
5. Letvin N.L., Linch D.C., Beardsley G.P., McIntyre K.W., Nathan D.G. Augmentation of fetal hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med. 310:1984;869-873.
6. Fibach E., Burk L.P., Schechter A.N., Noguchi C.T., Rodgers G.P. Hydroxyurea increases fetal hemoglobin in cultured erythroids cells derived from normal individuals and patients with sickle cell disease or β-thalassemia. Blood. 81:1993;1630-1635.
7. DeSimone J., Heller P., Hall L., Wiers D.Z. 1 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad SciUSA. 79:1982;4428-4431.
8. Perrine S.P., Ginder G.D., Faller D.V., et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders. N Engl J Med. 328:1993;81-86.
9. Elford H. Effect of hydroxyurea on ribonucleotide reductase. Biochem Biophys Res Commun. 33:1968;129-136.
10. Iyamu E.W., Roa P.D., Kopsombut P., Aguinaga Md.P., Turner E.A. New isocratic high performance liquid chromatographic procedure to assay the anti-sickling compound hydroxyurea with ultraviolet detection system. J Chromatogr B. 709:1998;119-126.
11. Vichinsky E.P., Lubin B.H. A cautionary note regarding hydroxyurea in sickle cell disease. Blood. 83:1994;1124-1128.
12. Wasserman T.H., Slavik M., Carter S.K. Clinical comparison of the nitrosoureas. Cancer. 36:1975;1258-1268.
13. Schein P.S. 1-Methyl-1-nitrosourea and dialkylnitrosamine depression of nicotinamide adenine dinucleotide. Cancer Res. 29:1969;1226-1232.
14. Arwich A., Fletcher W., Klotz J., et al. 5-FU vs combination therapy with tubercidin, streptozotocin, and 5-FU in the treatment of pancreatic carcinomas. J Surg Oncol. 12:1979;267-273.
15. Zhao K.M., Chen J.M., Zuo H.Z., Wu Y. Modulation of O6-methyltransferase-mediated nimustin resistance in recurrent malignant gliomas by streptozotocin - a preliminary report. Anticancer Res. 15:1995;645-648.
16. Schein P., Kahn R., Gordon P., Wells S., DeVita V. Streptozotocin for malignant insulinomas and carcinoid tumor. Arch Intern Med. 132:1973;555-561.
17. Panasc L.C., Fox P.A., Schein P.S. Structure activity studies of methylnitrosourea antitumor agents with reduced murine bone marrow toxicity. Cancer Res. 37:1977;3321-3328.
18. DeVita V.T. Jr. Principle of chemotherapy. DeVita V.T. Jr., Hellman S., Rosenberg S.A. Cancer, Principles and Practice of Oncology. 1989;5-20 Lippincott, Philadelphia.
19. Iyamu W.E., Adunyah S.E., Fasold H., et al. Enhancement of hemoglobin and F-cell production by targeting growth inhibition and differentiation of K562 cells with ribonucleotide reductase inhibitors (didox and trimidox) in combination with streptozotocin. Am J Hematol. 63:2000;176-183.
20. Dresler W.F.C., Stein R. Ueber den hydroxyharnstoff, justus liebigs. Ann Chem Pharmacol. 150:1869;242-252.
21. Chou T., Talalay P. Generalized equation for the analysis of inhibitions of Michaelis-Menten and higher-order kinetics systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem. 115:1980;207-216.
22. McLeod D.L., Shreeve M.M., Axelrad A.A. Improved plasma culture system for production of erythrocytic colonies in vitro: Quantitative assay method for CFU-E. Blood. 44:1974;517-534.
23. Horiuchi K., Fynn-Thompson F., Ohene-Frempong K. Degree of irreversible deformation of Hb F cells and non-F cells from patients with sickle cell disease. Exp Hematol. 22:1994;1058-1063.
24. Horiuchi K., Osterhout M., Bekoe N., Kamma H., Hirokawa K. Estimation of Hb F levels in individual red cells by fluorescence image cytometry. Cytometry. 20:1995;261-267.
25. Horiuchi K., Osterhout M.L., Ohene-Frempong K. Survival of F-reticulocytes in sickle cell disease. Biochem Biophys Res Commun. 217:1995;924-930.
26. Chou T., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:1989;27-55.
27. Yang Y.M., Pace B., Kitchens D., Ballas S.K., Shah A., Baliga B.S. BFU-E colony growth in response to hydroxyurea: correlation between in vitro and in vivo fetal hemoglobin induction. Am J Hematol. 56:1997;252-258.
28. Ou C.N., Rognerud C.L. Rapid analysis of hemoglobin variants by cation-exchange HPLC. Clin Chem. 39:1993;820-824.
29. Baliga B.S., Pace B.S., Chen H., Shah A.K., Yang Y. Mechanism for fetal hemoglobin induction by hydroxyurea in sickle cell erythroid progenitors. Am J Hematol. 65:2000;227-233.
30. Moore E.C., Hubert R.B. The inhibition of ribonucleoside diphosphate reductase by hydroxyurea, guanazole and pyrozoloimidazole (IMPY). Cory J.G., Cory A.H. International Encyclopedia of Pharmacology and Therapeutics. 1989;165 Pergamon, Oxford.
31. Charache S. Fetal hemoglobin, sickling and sickle cell disease. Adv Pediatr. 37:1990;1-31.
32. Charache S., Dover G.H., Moore R.D., et al. Hydroxyurea effects on hemoglobin F production in patients with sickle cell disease. Blood. 79:1992;2555-2565.
33. Desesso J.M., Scialli A.R., Goerringer G.C. D-mannitol, a specific hydroxyl free radical scavenger, reduces the developmental toxicity of hydroxyurea in rabbits. Teratology. 49:1994;248-259.
34. Iyamu W.E., Fasold H., Roa D., Aguinaga Md.P. Hydroxyurea-induced oxidative damage of hemoglobin in vitro: Amelioration by radical scavengers. J Clin Lab Anal. 15:2001;1-7.
35. Rodgers G.P. Pharmacological modulation of fetal hemoglobin. Embury S.H., Hebbel R.P., Mohandas N., Steinberg M.H. Sickle Cell Disease: Basic Principles and Clinical Practice. 1994;829 Raven Press, Ltd, New York.
36. Rodgers G.P., Dover G.J., Noguchi C.T., Schechter A.N., Niehuis A.W. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. N Engl J Med. 322:1990;1037-1045.
37. DeSimone J., Heller P., Biel S.I. Stimulation of fetal hemoglobin synthesis following stress erythropoiesis. Stamatoyannopoulos G., Niehuis A.W. Fetal Hemoglobin and Stress Erythropoiesis. Cellular and Molecular Regulation of Hemoglobin Switching. 1979;139-151 Grune & Stratton, New York.
38. Young C.W., Hodas S. Hydroxyurea: Inhibitory effects on DNA metabolism. Science. 146:1964;1171-1174.
39. Cioe' L., McNab A., Hubbell H.R., Meo P., Curtis P., Rovera G. Differential expression of globin genes in human leukemia K562 cells induced by hemin or butyric acid. Cancer Res. 41:1981;237-243.
40. Kohn K.W. Interstrand cross-linking of DNA by 1,3-Bis(2-chloroethyl)-1-nitrosourea and other 1-(2-haloethyl)-1-nitrosoureas. Cancer Res. 37:1977;1450-1454.
41. Ewig R.A.G., Kohn K.W. DNA-protein cross-linking and DNA inter-strand cross-linking by haloethylnitrosoureas in L1210 cells. Cancer Res. 38:1978;3197-3203.
42. Veith R., Galanello R., Papayannopoulou T., Stammatoyannopoulos G. Stimulation of F-cell production in patients with sickle cell disease treated with cytarabine or hydroxyurea. N Engl J Med. 313:1985;1571-1575.